Evidence map›Paper›PMID 39697047›Full record

ArticleInternational journal of cancer2025

Interval cancer risk after the upper age limit of screening has been reached: Informing risk stratification in FIT-based colorectal cancer screening.

Brenda J van Stigt, Iris Lansdorp-Vogelaar, Manon C W Spaander, Anneke J van Vuuren, Evelien Dekker, Folkert J van Kemenade, Iris D Nagtegaal, Monique E van Leerdam, Esther Toes-Zoutendijk

Abstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Brenda J van StigtDepartment of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.ORCID 0009-0005-4625-7666
Iris Lansdorp-VogelaarDepartment of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0002-9438-2753
Manon C W SpaanderDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
Anneke J van VuurenDepartment of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
Evelien DekkerDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Folkert J van KemenadeDepartment of Pathology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
Iris D NagtegaalDepartment of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Monique E van LeerdamDepartment of Gastrointestinal Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Esther Toes-ZoutendijkDepartment of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0003-4001-2949

Funding

Rijksinstituut voor Volksgezondheid en Milieu
6 · The paper itself

Abstract

Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in interval CRC risk among individuals who had reached the upper age limit of screening (75 years). Individuals with a negative FIT (<47 μg Hb/g feces) in the final round of the Dutch CRC screening program were selected from the national screening database and linked to the national cancer registry to identify CRCs diagnosed within 24 months (interval CRCs). Survival analyses assessed whether sex and last fecal hemoglobin (f-Hb) concentration were associated with interval CRC risk. A multivariable logistic regression assessed whether sex, last f-Hb concentration and screening round were associated with stage distribution (early vs. late). Last f-Hb concentrations were considered detectable when they were >0 μg Hb/g feces. Among 305,761 individuals with a complete follow-up (24 months), 661 were diagnosed with interval CRC (21.6 per 10,000 negative FITs). Individuals with detectable f-Hb (15%) were 5 times more likely to be diagnosed with interval CRC than those without (HR 4.87, 95%CI: 4.19-5.65). Moreover, their cancers were more often detected at a late stage compared to individuals without detectable f-Hb (OR 1.45, 95%CI: 1.06-2.01). Our results show that interval CRC risk among individuals aged ≥75 differs substantially by last f-Hb concentration, indicating a uniform age to stop screening is suboptimal. Future research, taking into account multiple screening rounds and FIT results, should determine the optimal risk-stratified screening strategy.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerAgedAge FactorsFecesFemaleHemoglobinsHumansMaleMass ScreeningMiddle AgedNetherlandsOccult BloodRisk AssessmentRisk FactorsHemoglobinsfecal immunochemical testhemoglobin concentrationpersonalized screeningscreening colorectal cancer

Identifiers

PMID39697047
PMCPMC11887016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.